When Hoechst Marion Roussel pulled Seldane from the U.S. market in 1997 and the Food and Drug Administration formally withdrew its approval effective 4 November 1998, the official posture was prudent stewardship; the documented record shows the company removing a drug it had known to be conditionally lethal for at least six years, and doing so only once it had a patented, profitable substitute ready to sell. Seldane (terfenadine), synthesized by Richardson-Merrell chemists in 1973 and marketed in the United States in 1985 as the world’s first nonsedating antihistamine, was a genuine therapeutic advance: it relieved hay fever without the drowsiness that made older antihistamines hazardous to drivers and workers. That advance concealed a defect in the molecule itself.
The gap between promise and harm lay in pharmacokinetics. Terfenadine as swallowed was a prodrug, almost entirely converted by the liver enzyme CYP3A4 into an active metabolite that did the antihistamine work. The unconverted parent compound, however, blocked the hERG (Kv11.1) cardiac potassium channel, prolonging the QT interval and inviting torsades de pointes, a chaotic ventricular rhythm that can kill within minutes. So long as metabolism was brisk, parent levels stayed trivial and the heart was safe. But any common CYP3A4 inhibitor — the antifungals ketoconazole and itraconazole, the macrolide antibiotics erythromycin and clarithromycin, even a glass of grapefruit juice — could throttle that conversion, let the parent drug pile up, and convert an allergy pill into an arrhythmogen. A patient stable for years could be killed by a course of antibiotics for a sinus infection.
The verdict is therefore plain at the outset: the danger was not a late surprise but a measured, published mechanism. FDA reports flagged ventricular arrhythmias by June 1990; a boxed warning followed in July 1992; and the landmark Honig study in JAMA in March 1993 demonstrated, in healthy volunteers, that ketoconazole co-administration made parent terfenadine accumulate and the QT interval lengthen. For most of the drug’s life the response was a warning label on a product that remained on pharmacy shelves and, for a time, was even pursued for over-the-counter status.
What finally ended Seldane was not the body count but the chemistry of replacement. The active metabolite — fexofenadine — carried the antihistamine benefit without the parent compound’s hERG liability. Marion Merrell Dow’s successor patented it, the FDA approved it as Allegra in July 1996, and only then did the maker withdraw Seldane and the FDA move to revoke approval. Terfenadine became the first blockbuster pulled for QT-related arrhythmia, the case that taught regulators to screen new drugs against the hERG channel, and a byword for a harm that was understood, labeled, and tolerated until a safer money-maker was ready.
When Janssen Pharmaceutica — the Belgian unit of Johnson & Johnson — announced on 23 March 2000 that it would stop general U.S. marketing of Propulsid, it presented the move as a precaution; the documented record shows a drug the company’s own labels had flagged as potentially lethal since 1995, kept on the open market for five more years while prescriptions ran past thirty million. Propulsid (cisapride) was a gastrointestinal prokinetic approved by the U.S. Food and Drug Administration in 1993 for nighttime heartburn from gastroesophageal reflux. It worked by speeding the gut, but it also blocked a cardiac potassium channel, prolonging the QT interval and, in vulnerable patients, triggering torsades de pointes — a chaotic ventricular arrhythmia that can stop the heart.
The gap between the indication and the harm was the whole tragedy. Cisapride was approved for adult reflux, but its danger concentrated in people who should never have received it: patients taking common interacting drugs — the macrolide antibiotics erythromycin and clarithromycin, the antifungals ketoconazole, itraconazole and fluconazole — that raised cisapride’s blood levels, and patients with underlying cardiac or metabolic risk. By the FDA’s accounting, of the 341 serious arrhythmias and 80 deaths reported through December 1999, roughly 85 percent occurred in patients with a recognized contraindication or risk factor. The drug was, in effect, safe in the population that did not need protecting and dangerous in the population that did.
The verdict is therefore plain at the outset: an approved, widely prescribed heartburn pill killed through interactions its manufacturer and the FDA had named in the label years before the withdrawal, and a meaningful share of the dead were infants and children who received it off-label for colic and reflux even though it was never approved for pediatric use. One observational study of roughly 58,000 premature infants found that about a fifth had been given cisapride.
What followed was a slow regulatory unwind and a mass-tort settlement. Janssen halted general sale effective 14 July 2000, retaining only a tightly controlled limited-access protocol; in 2004 Johnson & Johnson agreed to pay up to $90 million to resolve claims that the drug caused some 300 deaths and nearly 16,000 injuries. Propulsid became the textbook case of a “Dear Doctor” letter and a black box that did not change prescribing fast enough to stop the dying.
When Hoffmann-La Roche pulled Posicor from the U.S. market on 8 June 1998, just under a year after the Food and Drug Administration approved it in June 1997, the company framed the move as a precaution against drug interactions; the documented record shows that the molecule’s defining pharmacology — potent, mechanism-based inhibition of the liver enzyme cytochrome P450 3A4 — made it a hazard the moment it was co-prescribed with the ordinary medicines a hypertension or angina patient already took. Posicor (mibefradil), marketed as a first-in-class blocker of low-voltage T-type calcium channels, was promoted as a cleaner, more selective antihypertensive. It instead became one of the fastest major drug withdrawals of its era, undone not by a flaw in what it did to the heart but by what it did to the metabolism of dozens of unrelated drugs.
The gap between promise and harm was structural, not incidental. By slowing CYP3A4 — the enzyme that clears a large fraction of all prescription drugs — mibefradil let co-administered medicines accumulate to toxic levels. Statins such as simvastatin built up until muscle dissolved into the bloodstream (rhabdomyolysis), threatening the kidneys; antiarrhythmics, certain antihistamines, calcium-channel blockers and beta-blockers stacked into bradycardia, shock, and cardiac arrest. By the time of withdrawal more than 25 medications were known to be dangerous in combination with Posicor, and the drug was being taken by almost 200,000 Americans and nearly twice that number worldwide.
The verdict here is therefore plain at the outset. This was not a slow-burn safety signal suppressed over years, as with some withdrawals; it was a foreseeable consequence of the drug’s own measured pharmacokinetics, surfacing within months of launch. A particularly damning cluster, reported in JAMA in 1998, described patients who — following the very label advice to switch off Posicor onto another agent — went into shock within twelve hours, one of whom died, because mibefradil’s enzyme inhibition persisted for days after the last dose.
The reckoning was swift rather than litigious. Roche withdrew the drug globally, the FDA documented the action in the Federal Register, and the episode became a standard teaching case in clinical pharmacology: the canonical example of how a single potent CYP3A4 inhibitor can convert routine co-prescription into mass interaction risk, and how a list of contraindicated drugs that keeps growing after launch is itself the warning.